Acceptability, Compliance, and Safety of Non-small Cell Lung Cancer Cachectic Participants Continuing Compassionate Access in the ACCeRT Clinical Study

Objective: Cancer cachexia is defined as: a ‘multifactorial syndrome’, and it has been suggested that multitargeted approach required in its management. High prevalence seen within non-small cell lung cancer, patients may continue to experience post end of anti-cancer treatment, the late/end stage.Material Methods: Participants who had completed week 20/End Trial visit main Auckland’s Cachexia evaluating Resistance Training (ACCeRT) study were invited with treatment under compassionate use. could 2.09 g eicosapentaenoic acid (EPA), 300 mg COX-2 inhibitor (celecoxib), once daily; plus two sessions per progressive resistance training (PRT), 20 oral essential amino acids (EAA); high leucine, split dose over three days each session. Data was collected on acceptability, compliance adherence medication/PRT sessions. Secondary endpoints included: change body weight fat free mass, handgrip leg strength, Functional Assessment Anorexia/Cachexia Therapy, Multidimensional Fatigue Symptom Inventory-Short Form, World Health Organization Quality Life — BREF, Glasgow prognostic score, pro-inflammatory cytokines.Results: All six participants, ACCeRT study, opted Acceptability remained high, overall last study/PRT 81.0% for EPA, 98.8% celecoxib, 78.9% PRT 77.2% EAA. continued lose Fat-Free Mass, along reduced albumin increased C-Reactive protein levels. Mean time 78 days, mean survival 257 (140 + 117).Conclusion: Non-small cancer (NSCLC) cachectic are willing be enrolled onto multi-targeted regimen, benefit from symptom management even during their late/refractory stage.